DEVELOPING A HOLISTIC GLP-1 STRATEGY
We take an evidence-based approach to GLP-1 drugs, working with our partners to develop individualized strategies that promote clinically appropriate use and consider total cost of care, long-term value and member health outcomes.
REAL-WORLD ANALYSIS
The impact of GLP-1s
Glucagon-like peptide-1 agonists, or GLP-1s, have historically been used to manage type 2 diabetes. But there has also been a substantial increase in people using these drugs for weight loss, causing demand to skyrocket. In a recent study, Prime Therapeutics and Magellan Rx found only 27% of individuals were still using GLP-1s for weight loss a year after they began treatment – and revealed increased health care costs of $7,727 per person.1 As GLP-1s continue to transform the health care landscape, we offer clinical experts who help our partners stay on the forefront of this dynamic trend, delivering trusted, evidence-based insights.
CLINICAL PERSPECTIVES
The evolution of GLP-1s
When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend.² So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program. You can learn more about the latest GLP-1 trends, the drug pipeline and ways to capitalize on new opportunities.
Clinical insights
Holistic solutions for weight management
Obesity has grown in prevalence over recent decades, with nearly 73.1% of adults in the U.S. who are either overweight or obese. In addition to the health impact obesity can have, it’s also costing the health care system almost $173B per year. We’ve published a new white paper outlining where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and providing our expert perspective on what it takes to deliver a whole-person approach to sustainable weight management.
PODCASTS
Hear from our GLP-1 experts
Stay on top of the latest news
Regular updates from our newsroom
In the news
May 8, 2024
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes
Journal of Managed Care & Specialty Pharmacy (JMCP)
Perspectives
May 7, 2024
Prime/MRx helps clients and members navigate drug shortages
Constant communication across the supply chain limits disruption when a drug is unavailable
Perspectives
May 1, 2024
Prime Therapeutics releases new clinical insights report, “Weight management: A holistic journey”
Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss
1 Internal analysis, 2023
2 Internal analysis, 2023, based on GLP-1 list prices at time of publishing, including but not limited to Wegovy and Zepbound